SCHEMBL4425779

SCHEMBL4425779

CC(C)(C)c1ccc(C(=O)N2CC3C(C2)C3C(=O)Nc2ccc(N3CCC(N4CCCC4)C3)nc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.48
ADRA1A P35348 4/20 0.44
HDAC1 Q13547 1/20 0.42
KCNH2 Q12809 1/20 0.42
MCHR1 Q99705 1/20 0.42
L3MBTL3 Q96JM7 4/20 0.41
L3MBTL1 Q9Y468 4/20 0.41
FASN P49327 2/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PANK3 Q9H999 1/20 0.40
MBTD1 Q05BQ5 1/20 0.39
TP53BP1 Q12888 1/20 0.39
L3MBTL4 Q8NA19 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4426434 0.87 TRPV1 (0.45) TRPV1ADRA1AHDAC1KCNH2MCHR1
SCHEMBL4417790 0.84 MAPT (0.49) TRPV1L3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL4414899 0.80 TRPV1 (0.43) TRPV1ADRA1AL3MBTL3L3MBTL1ALDH1A1
SCHEMBL4415691 0.74 TRPV1 (0.52) TRPV1MCHR1FASNMEN1ALDH1A1
SCHEMBL4423657 0.73 MAPT (0.42) TRPV1ADRA1AALDH1A1SMN1; SMN2
SCHEMBL2180684 0.73 ADRA1A (0.37) TRPV1ADRA1AHDAC1L3MBTL3L3MBTL1
SCHEMBL8291593 0.73 MAPT (0.56) ADRA1AMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL4419310 0.72 TRPV1 (0.42) TRPV1MEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL4418100 0.72 MCHR1 (0.46) TRPV1KCNH2MCHR1L3MBTL3MEN1
SCHEMBL18887288 0.72 ADRA1A (0.36) TRPV1ADRA1AHDAC1L3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 TRPV1 1359/4885ADRA1A 618/4885HDAC1 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.